💊 Fueling India’s Pharma Future: How the Rs. 1,100 Crore Boost and 12.6% Budget Rise Can Transform Healthcare
In a year where India’s Union Budget 2026-27 aimed to
From Our Blog
Blog
From Sneezes to Solutions: Why Cetirizine and Levocetirizine Dominate India’s Antihistamine Market
Allergies have quietly become one of India’s most common lifestyle
Biopharma SHAKTI: India’s Bold Leap to Lead the Global Biopharmaceutical Revolution
The Union Budget 2026 presented by Finance Minister Nirmala Sitharaman
India’s New Regulatory Leap: Easing Drug Trials, Energising Pharma Innovation
In a landmark move that could reshape the trajectory of
Coming Home to Change: Will 2026 Be the Breakthrough Year for India’s Life Sciences Revolution?
As India steps boldly into 2026, the nation’s life sciences
New Dawn in Indian Pharma: Why Revised Schedule M Norms Must Be Enforced From January 1
In a decisive move that reverberates across the Indian pharmaceutical
When Indian Pharma Made History: How Wockhardt’s Zaynich Sparked a 27% Share Surge
The stock market waited — and then it roared. In
From Tragedy to Reform: How India Is Reinforcing Drug Safety After Cough Syrup Deaths
A disturbing pattern of child deaths linked to contaminated cough
From Burden to Breakthrough: The Rise of GLP-1 Shots in India’s Diabetic Journey
Diabetes has long cast a heavy shadow across India, earning
When Medicine Becomes a Risk: Why India’s Drug Regulator Is Targeting Small and Medium Pharma Players
In recent months, the Drugs Controller General of India (DCGI)
